Evidence map›Paper›PMID 28118365›Full record

ArticlePloS one2017

MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development.

Sahar Harati, Lee A D Cooper, Josue D Moran, Felipe O Giuste, Yuhong Du, Andrei A Ivanov, Margaret A Johns, Fadlo R Khuri, Haian Fu, Carlos S Moreno

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sahar HaratiDepartment of Biomedical Informatics, Emory University, Atlanta, Georgia, United States of America.
Lee A D CooperDepartment of Biomedical Informatics, Emory University, Atlanta, Georgia, United States of America.
Josue D MoranGraduate Program in Cancer Biology, Emory University, Atlanta, Georgia, United States of America.
Felipe O GiusteMedical Scientist Training Program, Emory University, Atlanta, Georgia, United States of America.
Yuhong DuWinship Cancer Institute, Emory University, Atlanta, Georgia, United States of America.
Andrei A IvanovDepartment of Pharmacology, Emory University, Atlanta, Georgia, United States of America.
Margaret A JohnsDepartment of Pharmacology, Emory University, Atlanta, Georgia, United States of America.
Fadlo R KhuriWinship Cancer Institute, Emory University, Atlanta, Georgia, United States of America.
Haian FuWinship Cancer Institute, Emory University, Atlanta, Georgia, United States of America.
Carlos S MorenoDepartment of Biomedical Informatics, Emory University, Atlanta, Georgia, United States of America.ORCID http://orcid.org/0000-0002-5582-0028
Emory University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
HIGH THROUGHPUT PROTEIN-PROTEIN INTERACTION INTERROGATION IN CANCERU01CA168449 · NCI · EMORY UNIVERSITY · PI FU, HAIAN · 2012 to 2016
$4.2M
NCI NIH HHS U01 CA168449NIGMS NIH HHS T32 GM008169
6 · The paper itself

Abstract

Protein-protein interactions (PPIs) mediate the transmission and regulation of oncogenic signals that are essential to cellular proliferation and survival, and thus represent potential targets for anti-cancer therapeutic discovery. Despite their significance, there is no method to experimentally disrupt and interrogate the essentiality of individual endogenous PPIs. The ability to computationally predict or infer PPI essentiality would help prioritize PPIs for drug discovery and help advance understanding of cancer biology. Here we introduce a computational method (MEDICI) to predict PPI essentiality by combining gene knockdown studies with network models of protein interaction pathways in an analytic framework. Our method uses network topology to model how gene silencing can disrupt PPIs, relating the unknown essentialities of individual PPIs to experimentally observed protein essentialities. This model is then deconvolved to recover the unknown essentialities of individual PPIs. We demonstrate the validity of our approach via prediction of sensitivities to compounds based on PPI essentiality and differences in essentiality based on genetic mutations. We further show that lung cancer patients have improved overall survival when specific PPIs are no longer present, suggesting that these PPIs may be potentially new targets for therapeutic development. Software is freely available at https://github.com/cooperlab/MEDICI. Datasets are available at https://ctd2.nci.nih.gov/dataPortal.

Indexed as

Drug DiscoverySoftwareAdenocarcinomaAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCluster AnalysisData MiningGene Knockdown TechniquesHumansLung NeoplasmsMolecular Targeted TherapyMutationNeoplasm ProteinsNeural Networks, ComputerProtein Interaction MappingRNA InterferenceAntineoplastic AgentsNeoplasm ProteinsRNA, Small Interfering

Identifiers

PMID28118365
PMCPMC5261804
OpenAlexW2582340064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.